Nama's AI scorecard currently rates Ocular Therapeutix Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does OCUL report earnings?

Ocular Therapeutix's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.35.

What is the OCUL price target?

The median analyst price target from 11 analysts is $27.00, with a range of $14.00 – $34.00.

Is OCUL Shariah compliant?

Nama's AAOIFI-style screen reads Ocular Therapeutix as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Ocular Therapeutix (OCUL)

Healthcare · Biotechnology · NASDAQ

Ocular Therapeutix (OCUL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.45B and a free-cash-flow yield of -17.6%. Over the most recent reported fiscal year, revenue declined 18.5%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -32.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-59.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.45B
Trailing P/E	—
Price / book	2.8
Price / sales	27.5
FCF yield	-17.6%
Dividend yield	—
Gross margin	87.1%
Operating margin	-603.0%
Net margin	-579.1%
Revenue growth (YoY)	-18.5%
Revenue growth (3-yr annual)	+0.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

OCUL earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.35). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 3, 2026	-$0.35	-$0.39	+10.3%	$13.47M
Q1 2026	May 5, 2026	-$0.40	-$0.31	-29.0%	$10.79M
Q4 2025	Feb 5, 2026	-$0.29	-$0.34	+14.7%	$13.25M
Q3 2025	Nov 4, 2025	-$0.38	-$0.35	-8.6%	$14.54M

OCUL analyst price target

Median target $27.00 from 11 analysts, ranging $14.00 – $34.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live OCUL data on Nama Insights →

OCUL FAQ

Is OCUL a buy?: Nama's AI scorecard currently rates Ocular Therapeutix Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does OCUL report earnings?: Ocular Therapeutix's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.35.
What is the OCUL price target?: The median analyst price target from 11 analysts is $27.00, with a range of $14.00 – $34.00.
Is OCUL Shariah compliant?: Nama's AAOIFI-style screen reads Ocular Therapeutix as Not Shariah Compliant. At least one of the three ratios or the industry test failed.